News Releases

Servier's VORANIGO® (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma

Servier Initiates Critical Dialogue on AYA Cancer Survivorship at ASCO 2024

Servier Highlights Commitment to Improving Cancer Outcomes at ASCO 2024

Servier Ranks 1st Across Several Categories in 2023-2024 PatientView U.S. Corporate Reputation Survey

Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D

Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma

FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma

CStone sells to Servier its exclusive rights to TIBSOVO®in Greater China and Singapore

Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition Through New Data Spotlighting Real-World Treatment Patterns and Clinical Outcomes of Tibsovo® Use at ASH 2023

Servier Expands Base4 Partnership to Advance Neuroscience Drug Development